These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24392980)

  • 1. Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.
    Millen BA; Dmitrienko A; Song G
    J Biopharm Stat; 2014; 24(1):94-109. PubMed ID: 24392980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-to-event analysis with treatment arm selection at interim.
    Di Scala L; Glimm E
    Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian statistical methods in public health and medicine.
    Etzioni RD; Kadane JB
    Annu Rev Public Health; 1995; 16():23-41. PubMed ID: 7639872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive methods: when and how should they be used in clinical trials?
    Porcher R; Lecocq B; Vray M;
    Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations.
    Millen BA; Dmitrienko A; Mandrekar SJ; Zhang Z; Williams D
    Ther Innov Regul Sci; 2014 Jul; 48(4):453-462. PubMed ID: 30235572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian adaptive D-optimal design with delayed responses.
    Li J; Fu H
    J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
    Atkinson AC; Biswas A
    Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians.
    Kalil AC; Sun J
    Crit Care Med; 2014 Oct; 42(10):2267-77. PubMed ID: 25226118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and proof of concept.
    Ferber G
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl C():35-40. PubMed ID: 12575486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.